摘要
目的 观察拉米夫定与胸腺肽α1 联合应用治疗慢性乙型肝炎的疗效。方法 选择 66例慢性乙型肝炎患者 ,随机分成两组 :联合治疗组 3 3例 ,应用拉米夫定 10 0mg/d ,口服 ,疗程 12个月 ,胸腺肽α1 1 6mg/次 ,皮下注射 ,2次 /周 ,连续 6个月 ;对照组仅给拉米夫定 10 0mg/d ,口服 ,疗程 12个月。结果 治疗后 6个月、12个月时 ,联合治疗组HBeAg转阴及HBeAg/抗 -HBe转换方面与拉米夫定组有明显差异性 (P <0 0 5 )。结论 拉米夫定与胸腺肽α1 联合应用治疗慢性乙型肝炎的确具有协同作用 。
Objective To observe the efficacy of treating chronic hepatitis B using lamivudine combining with thymosin α 1. Method 66 patients with chronic hepatitis B were randomly divided into combining treatment group(33cases) and lamivudine group(33cases),The combining group was treated with Lamivudine,100mg/d,oraly,the therapeutical course was 12 months.Combining thymosin α 1,1.6mg,two times each week,subcutaneously.The therapeutical course was 6 mouths.Lamivudine group was treated with lamivudine,100mg/d,oraly,the therapeutical course was 12 months.Results At 6,12months of treatment HBeAg negative rate,anti-HBe positive rate was higher in combining treatment group than in lamivudine group(P<0.05).Conclusion Treating chronic hepatitis B using lamivudine combining with thymosin α 1 has a coordinated effect.
出处
《中国厂矿医学》
2004年第2期93-93,共1页
Chinese Medicine of Factory and Mine
